EUVIMEDEUVIMED entdecken
Open Access

Comparative Effectiveness of Individual DPP-4 Inhibitors on Kidney Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: A Target Trial Emulation

Stacey M Sklepinski iD, Jeph Herrin, Joshua J Neumiller, Eric C Polley, Kavya Sindhu Swarna, Yihong Deng, Rodolfo J Galindo, Guillermo E Umpierrez, Joseph S Ross, Juan P Brito, Victor M Montori, Mindy M Mickelson und 1 weitere

Diabetes Obesity and Cardiometabolic CARE · 01.07.2026 · 1 (4) · 628-637

DOI: 10.2337/doc26-0025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Obesity and Cardiometabolic CARE, online erschienen am 16.07.2026. Verfasst von Stacey M Sklepinski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Advocate Lutheran General Hospital, Park Ridge, IL. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Patient-Centered Outcomes Research Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To examine kidney disease outcomes associated with dipeptidyl peptidase 4 inhibitors (DPP-4i). RESEARCH DESIGN AND METHODS In this target trial emulation, claims data from enrollees in commercial, Medicare Advantage, and traditional Medicare health plans were used to identify adults ≥21 years old with type 2 diabetes, with moderate cardiovascular risk, and without stage 3 or worse chronic kidney disease (CKD) initiating alogliptin, linagliptin, saxagliptin, or sitagliptin between 2014 and 2021. The primary outcome was a composite of incident CKD stages 3–5, kidney failure, or kidney replacement therapy. Random treatment assignment was emulated using propensity scores, estimated using the super learner ensemble method and incorporated as inverse probability of treatment weights into proportional hazards models. RESULTS The weighted study cohort included 3,026 individuals starting alogliptin, 38,213 starting linagliptin, 14,934 starting saxagliptin, and 115,091 starting sitagliptin. One year after treatment initiation, the primary outcome occurred in 1.4%, 2.7%, 2.2%, and 2.4% of patients initiating alogliptin, linagliptin, saxagliptin, and sitagliptin, respectively, increasing to 3.2%, 6.2%, 5.0%, and 5.4%, respectively, at 3 years. Alogliptin was associated with lower risk of stage 3 or worse CKD than linagliptin (hazard ratio [HR] 0.50; 95% CI 0.37–0.69), saxagliptin (HR 0.63; 95% CI 0.45–0.86), and sitagliptin (HR 0.58; 95% CI 0.42–0.79), while saxagliptin was associated with lower risk than linagliptin (HR 0.80; 95% CI 0.73–0.87). Conversely, linagliptin was associated with higher risk than sitagliptin (HR 1.15, 95% CI 1.10–1.21). CONCLUSIONS Alogliptin was associated with lower risk of moderate-to-severe kidney disease than other DPP-4i, while linagliptin was associated with higher risk. Limitations include lack of laboratory data and potential unmeasured confounding.

Autor:innen und Institutionen

  • Advocate Lutheran General Hospital, Park Ridge, IL.
  • Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT.
  • Department of Pharmacotherapy, Washington State University, Spokane, WA.
  • Providence Medical Research Center, Spokane, WA.
  • Department of Public Health Sciences, University of Chicago, Chicago, IL.
  • Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.

ORCID-Profile: Stacey M Sklepinski, Rozalina G McCoy

Förderung

  • Patient-Centered Outcomes Research Institute

Zitieren

APA

Sklepinski, S. M., Herrin, J., Neumiller, J. J., Polley, E. C., Swarna, K. S., Deng, Y., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Brito, J. P., Montori, V. M., Mickelson, M. M., & McCoy, R. G. (2026). Comparative Effectiveness of Individual DPP-4 Inhibitors on Kidney Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: A Target Trial Emulation. Diabetes Obesity and Cardiometabolic CARE, 1(4), 628-637. https://doi.org/10.2337/doc26-0025

Vancouver

Sklepinski SM, Herrin J, Neumiller JJ, Polley EC, Swarna KS, Deng Y, et al. Comparative Effectiveness of Individual DPP-4 Inhibitors on Kidney Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: A Target Trial Emulation. Diabetes Obesity and Cardiometabolic CARE. 2026;1(4):628-637. doi:10.2337/doc26-0025

BibTeX
@article{Sklepinski2026,
  author = {Sklepinski, Stacey M and Herrin, Jeph and Neumiller, Joshua J and Polley, Eric C and Swarna, Kavya Sindhu and Deng, Yihong and Galindo, Rodolfo J and Umpierrez, Guillermo E and Ross, Joseph S and Brito, Juan P and Montori, Victor M and Mickelson, Mindy M and McCoy, Rozalina G},
  title = {Comparative Effectiveness of Individual DPP-4 Inhibitors on Kidney Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: A Target Trial Emulation},
  journal = {Diabetes Obesity and Cardiometabolic CARE},
  year = {2026},
  volume = {1},
  number = {4},
  pages = {628--637},
  doi = {10.2337/doc26-0025}
}
Kostenlos starten →